Graded claim

CBG and neuroprotection

What does the evidence show for CBG and neuroprotection?

In two mouse models of Huntington's disease, CBG reduced neuroinflammation and helped preserve neurons. These are early animal findings, not evidence of benefit in people; no human studies exist.

grade: Lowpreclinical only
What reaching the next rung would take

Any one of these, on top of what our registry already holds:

  • one animal (preclinical) effect study from a research group not already counted here
  • one human trial of any size — including a small, short (acute / single-dose) one

The grade weighs the claim as a whole, across every study our registry holds on the question. How good any one of those papers is remains a separate matter, and you can judge each on its own terms.

Permalink

Studies behind this grade

2015

Neuroprotective properties of cannabigerol in Huntington's disease: studies in R6/2 mice and 3-nitropropionate-lesioned mice

Valdeolivas et al. · Neurotherapeutics · PMID 25252936 · study type: Animal · preclinical

animal model (R6/2 + 3-NP mice) · animal

PubMed →

Other conditions we cover

The CBG monograph covers the compound end to end, and the gap-map charts the questions nobody has tested yet.

CBG acts on α2-adrenoceptors, which help regulate blood pressure; anyone taking cardiovascular medication should consult a clinician before using CBG products. Nothing on this page is medical advice, and no statement here is a claim that CBG treats, cures, or prevents any condition. Grades are based on the studies we had checked as of 9 August 2026. Report a safety event. Peregrine Biopharma funds the platform and holds no editorial authority.